Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 28;8(4):528-550.
doi: 10.15326/jcopdf.2021.0213.

Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity

Heleen Demeyer  1   2 , Divya Mohan  3 , Chris Burtin  4 , Anouk W Vaes  5 , Matthew Heasley  6 , Russell P Bowler  7 , Richard Casaburi  8 , Christopher B Cooper  9 , Solange Corriol-Rohou  10 , Anja Frei  11 , Alan Hamilton  12 , Nicholas S Hopkinson  13   14 , Niklas Karlsson  15 , William D-C Man  13   16 , Marilyn L Moy  17   18 , Fabio Pitta  19 , Michael I Polkey  13   14 , Milo Puhan  11 , Stephen I Rennard  20 , Carolyn L Rochester  21   22 , Harry B Rossiter  8   23 , Frank Sciurba  24 , Sally Singh  25 , Ruth Tal-Singer  26 , Ioannis Vogiatzis  27 , Henrik Watz  28 , Rob Van Lummel  29 , Jeremy Wyatt  30 , Debora D Merrill  26 , Martijn A Spruit  4   5   31 , Judith Garcia-Aymerich  32   33   34 , Thierry Troosters  1 ; Chronic Lung Disease Biomarker and Clinical Outcome Assessment Qualification Consortium Task Force on Physical Activity
Affiliations

Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity

Heleen Demeyer et al. Chronic Obstr Pulm Dis. .

Abstract

Physical activity (PA) is of key importance for health among healthy persons and individuals with chronic obstructive pulmonary disease (COPD). PA has multiple dimensions that can be assessed and quantified objectively using activity monitors. Moreover, as shown in the published literature, variable methodologies have been used to date to quantify PA among individuals with COPD, precluding clear comparisons of outcomes across studies. The present paper aims to provide a summary of the available literature for the rationale behind using objectively measured PA and proposes a standardized methodology for assessment, including standard operating procedures for future research. The present paper, therefore, describes the concept of PA, reports on the importance of PA, summarizes the dimensions of PA, provides a standard operating procedure on how to monitor PA using objective assessments, and describes the psychometric properties of objectively measured PA. The present international task force recommends implementation of the standard operating procedure for PA data collection and reporting in the future. This should further clarify the relationship between PA and clinical outcomes, test the impact of treatment interventions on PA in individuals with COPD, and successfully propose a PA endpoint for regulatory qualification in the future.

Keywords: Physical activity; accelerometery; methodology; standardization.

PubMed Disclaimer

Conflict of interest statement

Dr. Heleen Demeyer is a post-doctoral research fellow of FWO Flanders; Drs.Divya Mohan and Ruth Tal-Singer are former employees and current shareholders of GlaxoSmithKline; Dr. Tal-Singer reports personal fees from Immunomet, and Vocalis Health. Dr. Mohan is a current employee of Genentech. Matthew Heasley is a full-time employee and shareholder at GlaxoSmithKline. Dr. Richard Casaburi reports personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Genentech, Respinova, and Regeneron. Dr. Christopher Cooper reports grants from the National Institutes of Health /the National Heart, Lung and Blood Institute, the Foundation of the National Institutes of Health and the COPD Foundation during the conduct of the study. He also reports personal fees from PulmonX, GlaxoSmithKline, NUVAIRA, and MGC Diagnostics, outside the submitted work. Dr. Stephen Rennard was employed by AstraZeneca and holds shares. Dr. Alan Hamilton is an employee of Boehringer Ingelheim (Canada) Ltd. Niklas Karlsson is employed by AstraZeneca. Dr. William Man reports grants from the National Institutes for Health, grants from the British Lung Foundation, personal fees from Jazz Pharmaceuticals, personal fees from Mundipharma, personal fees from Novartis, non-financial support from GlaxoSmithKline, and grants from Pfizer, outside the submitted work. Dr. Michael Polkey is a paid consultant for Philips Respironics, JFD, and has received fees for lecturing from Genzyme Sanofi, and GlaxoSmithKline. His institution has received fees for research from GlaxoSmithKline and Novartis, relating to Dr. Polkey’s work. Dr. Carolyn Rochester participates in clinical trials sponsored by AstraZeneca and has received personal fees for scientific advisory board participation from Glaxo SmithKline and Boehringer Ingelheim. Dr. Henrik Watz received payments for lectures/consulting honorarium/travel support from Almirall, AstraZeneca, BerlinChemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, and Novartis and received unrestricted research grants from AstraZeneca and GlaxoSmithKline. The employer of Dr. Watz (Pulmonary Research Institute at LungenClinic Groshansdorf) received compensation for participation in clinical trials and consulting fees from Almirall, Takeda, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Pfizer, TEVA, Bayer HealthCare, Revotar, Sterna, Roche, AB2BIO, and Philips. Dr. Martijn Spruit reports grants from the Netherlands Lung Foundation, grants from Stichting Astma Bestrijding, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingeheim, all outside the submitted work. Dr. Judith Garcia-Aymerich reports other from AstraZeneca, other from Chiesi, outside the submitted work. Dr. Thierry Trooster’s institute received speaker/consultancy fees on the topic of physical activity from Boehringer Ingelheim, AstraZeneca, Chiesi, and Bayer. All other authors have nothing to disclose relevant to the submitted work.

References

    1. Casaburi R,Celli B,Crapo J,et al. The COPD Biomarker Qualification Consortium. COPD. 2013;10(3):367-377.doi: https://doi.org/10.3109/15412555.2012.752807 - PubMed
    1. Troosters T,van der Molen T,Polkey M,et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115. doi: https://doi.org/10.1186/1465-9921-14-115 - PMC - PubMed
    1. Watz H,Pitta F,Rochester C,et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521-1537.doi: https://doi.org/10.1183/09031936.00046814 - PubMed
    1. Bowler R,Allinder M,Jacobson S,et al. Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD. BMJ Open Respir Res. 2019;6(1):e000350.doi: https://doi.org/10.1136/bmjresp-2018-000350 - PMC - PubMed
    1. Demeyer H,Louvaris Z,Frei A,et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72(5):415-423.doi: https://doi.org/10.1136/thoraxjnl-2016-209026 - PMC - PubMed